Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynektikFRA:A2P -0.60%71 EV-to-FCF is 19.01 as of Aug. 20, 2026, which is 98% above its 10-year median of 9.58. GuruFocus rates FRA:A2P with a GF Score™ of 71/100 and a GF Value™ of €67.64 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 407 Medical Devices & Instruments companies, Synektik ranks better than 61.43% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Synektik's Enterprise Value is €698.7 Mil.
Synektik's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €36.8 Mil. Therefore, Synektik's EV-to-FCF for today is 19.01.
The historical rank and industry rank for Synektik's EV-to-FCF or its related term are showing as below:
FRA:A2P'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.27 Med: 9.58 Max: 43.71
Current: 19.59
During the past 13 years, the highest EV-to-FCF of Synektik was 43.71. The lowest was -30.27. And the median was 9.58.
FRA:A2P's EV-to-FCF is ranked better than 61.43% of 407
companies
in the Medical Devices & Instruments industry
Industry Median: 24.75
vs FRA:A2P: 19.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Synektik's share price for today is €83.50.
Synektik's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.499.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Synektik EV-to-FCF Related Terms
Synektik EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Synektik's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Synektik's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Synektik's EV-to-FCF falls into.
Synektik's current Enterprise Value is €698.7 Mil.
Synektik's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €36.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synektik (FRA:A2P) has a EV-to-FCF of 19.01 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synektik and its competitors. This is 98% above median its historical median of 9.58. According to the industry distribution chart, Synektik ranks #157 out of 407 companies in the Medical Devices & Instruments industry, placing it in the top 38.6%.
Is Synektik's EV-to-FCF too high?
Synektik's current EV-to-FCF of 19.01 is 98% above median its 10-year median of 9.58. The Medical Devices & Instruments industry median EV-to-FCF is 24.75. Synektik's value of 19.01 is 23.2% below this industry median. Based on the distribution chart, Synektik ranks #157 out of 407 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Synektik has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #157 out of 407 companies for EV-to-FCF. This puts Synektik in the upper half of its industry. The industry median EV-to-FCF is 24.75. Synektik's value of 19.01 is 23.2% below this benchmark. While the company's 10-year median is 9.58 vs. the industry median of 24.75, Synektik has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.75, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current EV-to-FCF of 19.01 is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Synektik and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current EV-to-FCF is 19.01, which is 98% above median its own 10-year median of 9.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €67.64, compared to a current price of €83.50 — trading 23.4% above its estimated fair value. The current EV-to-FCF is 19.01, which is 98% above median its 10-year median of 9.58 and 23.2% below the Medical Devices & Instruments industry median of 24.75. Synektik's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Synektik (FRA:A2P), the current EV-to-FCF is 19.01 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (FRA:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €83.50 is trading 23.4% above its estimated GF Value™ of €67.64.
GuruFocus considers Synektik to be Modestly Overvalued.
Key valuation signals for FRA:A2P:
EV-to-FCF: 19.01 (98% above median its 10-year median of 9.58)
GF Value™: €67.64 vs. price of €83.50 (23.4% above fair value)
Industry Position: 23.2% below the Medical Devices & Instruments median (#157 of 407)
No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
71GF Score
Get the complete analysis for FRA:A2P
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2P has been successfully added to your 
